Fruquintinib

呋喹替尼

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameFruquintinib
Drug Alias NameFuquinitinibFurquitinib爱优特ElunateFRUZAQLA +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Vascular endothelial growth factor receptor 2
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[20] 
Global Approved IndicationsColorectal Neoplasms
Approved Indications in ChinaColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2018/09/04
Country/TerritoryCzechiaBelgiumUnited States +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHutchison Medipharma Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesConvalife (Shanghai) Co LtdHenan Provincial Cancer HospitalHutchmed (China) Ltd +[13] 
Inactive CompaniesTheraBionic IncBarbara Ann Karmanos Cancer InstituteSichuan University +[4] 
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[14] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsPancreatic Neoplasms +[6] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG